Investor Centre Analysts Reports

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Categories

Information

Analysts Reports

Immuron Limited: Immunity for the gut (November 2023)

Immuron Limited FY23 Results - Henslow Research (September 2023)

Immuron Limited Bioshares Report – (May 2023)

Immuron Limited 1H 2023 Results – Henslow Research (Mar 2023)

Immuron Equity Report (Oct 2019)

Immuron takes aim at the rapid growth of autoimmune diseases

Immuron surges 28pc after study shows tablets fight Bali Belly in US soldiers (Jan 2018)

Van Leeuwenhoeck Institute Updated Report (Nov 2017)

Emerging Biologics in Fatty-Liver and Infectious Disease Management (Sep 2017)

BioShares Report - Edition 687 (Mar 2017)

Van Leeuwenhoeck Institute Report - Substantial Re-rating in NASH (Feb 2017)

Van Leeuwenhoeck Institute Independent Research Note (Jan 2017)

SeeThru Equity Analyst Report (Feb 2016)

Red Chip C-Difficile Analyst Report (Jan 2016)

Red Chip Analyst Report (Aug 2015)

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information